One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Ferritin-induced NETs lead to cytokine storm in AOSD
Sarah OnuoraÂ
doi : 10.1038/s41584-022-00899-w
Volume 19 Issue 2, February 2023
AhR promotes suppressor cell function in Sjögren syndrome
Jessica McHughÂÂ
Hypoxia-modifying hydrogel supports stem cells for joint repair
Robert PhillipsÂÂ
Treg cell-inducing nanoparticles show promise for treating OA
Jessica McHughÂÂ
Gene-expression profiles predict rituximab response in SLE
Robert PhillipsÂÂ
‘Hyalinization’ for cartilage regeneration
Sarah OnuoraÂÂ
mTORC1 implicated in Still’s disease and MAS
Sarah OnuoraÂÂ
Cancer and cardiovascular risk with JAK inhibition
Jessica McHughÂÂ
Bimekizumab safe and effective for psoriatic arthritis
Jessica McHughÂÂ
New refinements aim to optimize articular cartilage tissue engineering
Nicole Schäfer & Susanne GrässelÂ
Progress continues in prediction of the response to treatment of RA
Myles J. Lewis & Costantino PitzalisÂ
MIS-C: myths have been debunked, but mysteries remain
Jane C. BurnsÂÂ
JAK inhibitors: new indication and emerging safety data in 2022
Peter NashÂÂ
New developments in electronic health record analysis
Jutta G. Richter & Christian ThielscherÂ
COVID-19 vaccination in individuals with inflammatory rheumatic diseases
Alla Skapenko & Hendrik Schulze-KoopsÂ
The decisive early phase of bone regeneration
Georg N. Duda, Sven Geissler, Sara Checa, Serafeim Tsitsilonis, Ansgar Petersen & Katharina Schmidt-BleekÂ
doi : 10.1038/s41584-022-00887-0
Bone has a remarkable endogenous regenerative capacity that enables scarless healing and restoration of its prior mechanical function, even under challenging conditions such as advanced age and metabolic or immunological degenerative diseases.
Busting the myth of methotrexate chronic hepatotoxicity
Vincent Di Martino, Delphine Weil Verhoeven, Frank Verhoeven, François Aubin, Jérome Avouac, Lucine Vuitton, Frédéric Lioté, Thierry Thévenot & Daniel WendlingÂ
doi : 10.1038/s41584-022-00883-4
Methotrexate is a key component of the treatment of inflammatory rheumatic diseases and the mainstay of therapy in rheumatoid arthritis. Hepatotoxicity has long been a concern for prescribers envisaging long-term treatment with methotrexate for their patients.
Vascular Behçet syndrome: from pathogenesis to treatment
Alessandra Bettiol, Fatma Alibaz-Oner, Haner Direskeneli, Gulen Hatemi, David Saadoun, Emire Seyahi, Domenico Prisco & Giacomo EmmiÂ
doi : 10.1038/s41584-022-00880-7
Behçet syndrome is a rare, chronic inflammatory disease of unknown aetiopathogenesis, most commonly presenting with mucocutaneous and ocular manifestations. Vascular involvement, most frequently superficial vein and deep vein thrombosis, can occur in up to 50% of patients with Behçet syndrome.
Ferritin-induced NETs lead to cytokine storm in AOSD
Sarah OnuoraÂ
doi : 10.1038/s41584-022-00899-w
Volume 19 Issue 2, February 2023
AhR promotes suppressor cell function in Sjögren syndrome
Jessica McHughÂÂ
Hypoxia-modifying hydrogel supports stem cells for joint repair
Robert PhillipsÂÂ
Treg cell-inducing nanoparticles show promise for treating OA
Jessica McHughÂÂ
Gene-expression profiles predict rituximab response in SLE
Robert PhillipsÂÂ
‘Hyalinization’ for cartilage regeneration
Sarah OnuoraÂÂ
mTORC1 implicated in Still’s disease and MAS
Sarah OnuoraÂÂ
Cancer and cardiovascular risk with JAK inhibition
Jessica McHughÂÂ
Bimekizumab safe and effective for psoriatic arthritis
Jessica McHughÂÂ
New refinements aim to optimize articular cartilage tissue engineering
Nicole Schäfer & Susanne GrässelÂ
Progress continues in prediction of the response to treatment of RA
Myles J. Lewis & Costantino PitzalisÂ
MIS-C: myths have been debunked, but mysteries remain
Jane C. BurnsÂÂ
JAK inhibitors: new indication and emerging safety data in 2022
Peter NashÂÂ
New developments in electronic health record analysis
Jutta G. Richter & Christian ThielscherÂ
COVID-19 vaccination in individuals with inflammatory rheumatic diseases
Alla Skapenko & Hendrik Schulze-KoopsÂ
The decisive early phase of bone regeneration
Georg N. Duda, Sven Geissler, Sara Checa, Serafeim Tsitsilonis, Ansgar Petersen & Katharina Schmidt-BleekÂ
doi : 10.1038/s41584-022-00887-0
Bone has a remarkable endogenous regenerative capacity that enables scarless healing and restoration of its prior mechanical function, even under challenging conditions such as advanced age and metabolic or immunological degenerative diseases.
Busting the myth of methotrexate chronic hepatotoxicity
Vincent Di Martino, Delphine Weil Verhoeven, Frank Verhoeven, François Aubin, Jérome Avouac, Lucine Vuitton, Frédéric Lioté, Thierry Thévenot & Daniel WendlingÂ
doi : 10.1038/s41584-022-00883-4
Methotrexate is a key component of the treatment of inflammatory rheumatic diseases and the mainstay of therapy in rheumatoid arthritis. Hepatotoxicity has long been a concern for prescribers envisaging long-term treatment with methotrexate for their patients.
Vascular Behçet syndrome: from pathogenesis to treatment
Alessandra Bettiol, Fatma Alibaz-Oner, Haner Direskeneli, Gulen Hatemi, David Saadoun, Emire Seyahi, Domenico Prisco & Giacomo EmmiÂ
doi : 10.1038/s41584-022-00880-7
Behçet syndrome is a rare, chronic inflammatory disease of unknown aetiopathogenesis, most commonly presenting with mucocutaneous and ocular manifestations. Vascular involvement, most frequently superficial vein and deep vein thrombosis, can occur in up to 50% of patients with Behçet syndrome.
